Statin-Based Palliative Therapy for Hepatocellular Carcinoma

Area of Science:

• Hepatocellular Carcinoma Research
• Oncology
• Pharmacological Interventions

Background:

• Most hepatocellular carcinoma (HCC) patients worldwide do not receive curative treatments.
• Palliative treatments like TACE, chemotherapy, and radiotherapy are common alternatives.
• The therapeutic effects of statins in HCC patients receiving palliative treatment are largely unknown.

Purpose of the Study:

• To evaluate the effects of statin use on HCC patients undergoing palliative treatment.
• To assess the impact of statins on mortality rates in HCC patients.
• To compare the efficacy of statin use in HBV-related versus non-HBV-related HCC.

Main Methods:

• Analysis of data from Taiwan's National Health Insurance claims and cancer registry databases (2001-2012).
• Inclusion of 20,200 HCC patients with HBV carrier-related HCC receiving palliative treatment (TACE, chemotherapy, radiotherapy).
• Comparison of outcomes between patients with and without statin use during palliative treatment.

Main Results:

• Statin use was associated with significantly lower HCC-specific deaths in all stages (I-IV) compared to non-statin users.
• Adjusted hazard ratios for all-cause and HCC-specific deaths decreased with palliative treatment plus statin use.
• Statin use showed stronger therapeutic effects in HBV-related HCC, reducing HCC-specific deaths by up to 50% in certain stages.

Conclusions:

• Palliative treatments combined with statins reduce mortality risk in HCC patients.
• Statins demonstrate therapeutic value as an adjuvant treatment, prolonging survival in advanced HCC.
• Statin-based palliative treatment significantly reduces deaths in early-stage HCC and may benefit patients unable to tolerate palliative therapies.